Cardior Pharmaceuticals: Pioneering Study Confirms Pivotal Role of Antisense microRNA Approach in the Treatment of Pathologic Hypertrophy of the Heart

Hanover, Germany, June 24, 2021 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiovascular diseases, announced today that results from a recent peer-reviewed study underlining the Company´s pioneering approach in the treatment of cardiac diseases were published in the Journal of the American College of Cardiology. The data confirm that the inhibition of the naturally occurring miR-132 microRNA via an antisense microRNA can prevent pathological cardiac remodeling in hypertrophic heart disease.